Dr Douglas Brand

Dr Douglas Brand is a Consultant Clinical Oncologist at University College Hospital Macmillan Cancer Centre, with a focus on gastrointestinal cancers. He provides nonsurgical treatments, radiotherapy, chemotherapy and immunotherapy for cancers of the oesophagus, stomach, pancreas, liver, bile ducts, colon, rectum, and anus.  After graduating with distinction in medicine from the University of Cambridge, Dr Brand completed specialist training in Clinical Oncology at leading institutions including The Christie Hospital, The Royal Marsden, and University College Hospital. His clinical interests lie in combined modality treatments, such as total neoadjuvant therapy for rectal cancer. He is the radiotherapy lead for UCLH in the ARTEMIS study exploring this approach. Dr Brand has advanced expertise in stereotactic body radiotherapy (SBRT) and proton beam therapy, precision techniques used to treat primary and metastatic liver and pancreatic cancers while minimising damage to healthy tissues. His academic work includes a Master’s degree in radiotherapy innovation and a PhD in machine learning for predicting treatment outcomes, undertaken at the Institute of Cancer Research. He went on to hold a Clinical Lectureship at UCL, continuing his research into AI-driven outcome prediction and proton therapy. He is the UCLH principal investigator for the PROTIEUS trial, examining proton therapy in oesophageal cancer.

Cancers Treated: Bowel Cancers (Colon, Rectum, Anal) Oesophagogastric cancers (Oesophagus, Stomach) Hepatobiliary cancers (Liver, Bile duct, Pancreas)